Challenges and successes in developing new therapies for hepatitis C. (Q36233823)

12 August 2017

1 reference

title

Challenges and successes in developing new therapies for hepatitis C. (English)

1 reference

12 August 2017

Raffaele De Francesco

series ordinal

1

1 reference

12 August 2017

Giovanni Migliaccio

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

436

1 reference

12 August 2017

7053

1 reference

12 August 2017

953-960

1 reference

https://scigraph.springernature.com/pub.10.1038/nature04080

12 August 2017

0 references

cites work

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Scope of worldwide hepatitis C problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Peptide-based inhibitors of the hepatitis C virus serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

"Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Biodistribution of phosphodiester and phosphorothioate siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Past, present, and future hepatitis C treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Interference of hepatitis C virus RNA replication by short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Caspase 8 small interfering RNA prevents acute liver failure in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

RNA interference in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Innate sensing of viruses by toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Plasmacytoid dendritic cells: linking innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

RNA interference and chemically modified small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

Substrate specificity of the hepatitis C virus serine protease NS3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

7 January 2021

Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

7 January 2021

Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

7 January 2021

RNA interference targeting Fas protects mice from fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

7 January 2021

TLRs: Professor Mechnikov, sit on your hat.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04080

7 January 2021

Identifiers

DOI

10.1038/NATURE04080

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference